Labiotech.eu

In Depth 24 Apr 2018

Can DIY Biology Ever Become a Big Player in Biotech?

Alongside university research and industry R&D, a third, parallel community actively uses tools and methods of the life sciences: biohackers. What are they, and what is their impact on biotech and the startup scene? One of the richest persons alive and one of the first hackers ever, Bill Gates, said that if he were young today […]

April 24, 2018 - 6 minutesmins - By External Contributor

News and Trends 23 Apr 2018

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […]

April 23, 2018 - 3 minutesmins - By Editorial Team

News and Trends 20 Apr 2018

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […]

April 20, 2018 - 2 minutesmins - By Alexander Burik

BenevolentAI Artificial Intelligence Fundraising

News and Trends 19 Apr 2018

Major $115M Fundraising Fuels AI Drug Development

BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […]

April 19, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 19 Apr 2018

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […]

April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Apr 2018

Finnish Rapid Molecular Diagnostic Test Enters European Market

Mobidiag, a Finnish biotech, has launched a diagnostic test that can rapidly detect the most common disease-causing microbes in the gut. The test can help manage infections more effectively at an earlier stage. Mobidiag has launched a molecular diagnostic test on the European market that checks patient samples for numerous bacterial targets, including the most […]

April 18, 2018 - 1 minutemin - By Alexander Burik

Interview 18 Apr 2018

What Lies Ahead for European Cell and Gene Therapies?

Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […]

April 18, 2018 - 5 minutesmins - By Alexander Burik

News and Trends 17 Apr 2018

How Low Can the Price of a Next Generation DNA Sequencer Go?

The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market. Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for […]

April 17, 2018 - 5 minutesmins - By External Contributor

More News! 16 Apr 2018

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves’ disease, one of the most common autoimmune diseases. Apitope has obtained positive clinical results indicating its treatment for Graves’ disease is safe and well-tolerated. A common autoimmune disease affecting the thyroid, Graves’ disease occurs when a patient’s immune system […]

April 16, 2018 - 2 minutesmins - By Alexander Burik

Adocia Double Hormone Diabetes Treatment

News and Trends 16 Apr 2018

French Double-Hormone Diabetes Treatment to be Tested in Humans for the First Time

Adocia, a French biotech, will initiate a Phase I clinical study to test a diabetes treatment that maximizes the effect of two blood sugar-lowering hormones. Adocia will start a Phase I clinical trial to test the safety and tolerability of its BioChaperone Pramlintide Insulin treatment to control blood sugar levels after a meal in type 1 […]

April 16, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 13 Apr 2018

This Israeli Biotech Targets Protein Translation to Fight Disease

Today, we’re taking a look at Anima Biotech, an Israeli company that is developing a new class of drugs that target protein translation to combat a range of diseases, including lung fibrosis, cancer, and Huntington’s disease. Mission: Since 2010, Anima Biotech has been targeting disease-causing proteins with a new class of drugs that control protein translation. […]

April 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Apr 2018

British Biotech Raises £29M Round to Fight Lung Disease

Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development. Enterprise Therapeutics, a British biotech, has raised £29M (€33M) in Series B from several investors including Forbion, one of the most active European life science VCs. In Enterprise, Forbion has found a replacement in its portfolio for the Dutch […]

April 12, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Can DIY Biology Ever Become a Big Player in Biotech?

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Major $115M Fundraising Fuels AI Drug Development

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Finnish Rapid Molecular Diagnostic Test Enters European Market

What Lies Ahead for European Cell and Gene Therapies?

How Low Can the Price of a Next Generation DNA Sequencer Go?

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

French Double-Hormone Diabetes Treatment to be Tested in Humans for the First Time

This Israeli Biotech Targets Protein Translation to Fight Disease

British Biotech Raises £29M Round to Fight Lung Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!